Jianmin Pharmaceutical Group Co., Ltd. Jianmin Pharmaceutical Group Co., Ltd. (600976.SS) is a China-based company principally engaged in the research, development, manufacturing, wholesale and retail of pharmaceuticals, with a primary focus on pediatric medicines, gynecological medicines and specialty traditional Chinese medicines. The company operates through two main segments: Pharmaceutical Production and Sales, which produces various Chinese patent medicines including flagship products such as Longmuzhuang bone granules for pediatric growth and nutrition, bowel relief capsules, spleen health blood tablets, Xiaojin capsules and pediatric Baotaikang tablets under the Jianmin, Longmu and Yekaitai brands, selling them to distributors, hospitals and pharmacies; and the Commercial segment, which purchases drugs from manufacturers and agents for distribution to lower-level channels, hospitals and retail outlets, alongside over-the-counter (OTC), medical and general health products, as well as traditional Chinese medicine consultation services. Founded in 1993 and headquartered at No. 484 Parrot Avenue, Hanyang District, Wuhan, China, it primarily serves the domestic market with approximately 2,345 employees and maintains a research institute dedicated to pediatric drug development. Recent developments include regulatory approval for a sinusitis drug trial in August 2025, marketing approval for furosemide oral solution, a subsidiary's 12.31 million yuan investment in preprocessing building renovations announced in late 2024, a 6.13% stake acquisition in HeraMED Limited completed in July 2024, and a planned donation of pharmaceuticals worth approximately 1 million yuan to earthquake-affected areas in Tibet in January 2025.